We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-0.42%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$137M
AUM Growth
-$1.43M
Cap. Flow
+$3.85M
Cap. Flow %
2.8%
Top 10 Hldgs %
73.24%
Holding
64
New
1
Increased
15
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
OVV icon
Ovintiv
OVV
+$2.58M
2
PRTA icon
Prothena Corp
PRTA
+$1.77M
3
PHR icon
Phreesia
PHR
+$1.6M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$933K
5
BDSX icon
Biodesix
BDSX
+$908K

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$2.06M
2
BMY icon
Bristol-Myers Squibb
BMY
+$2M
3
AMRN
Amarin Corp
AMRN
+$647K
4
UTHR icon
United Therapeutics
UTHR
+$610K
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$518K

Sector Composition

Rank Sector Weight
1 Healthcare 93.73%
2 Energy 3.94%
3 Consumer Staples 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INBX
26
DELISTED
Inhibrx, Inc. Common Stock
INBX
$800K 0.58%
70,448
+20,000
+40% +$294K
TSVT
27
DELISTED
2seventy bio
TSVT
$790K 0.57%
59,833
+25,500
+74% +$347K
DCGO icon
28
DocGo
DCGO
$67.6M
$785K 0.57%
110,000
– –
SLNO
29
DELISTED
Soleno Therapeutics
SLNO
$680K 0.49%
245,127
– –
NARI
30
DELISTED
Inari Medical, Inc. Common Stock
NARI
$680K 0.49%
10,000
+2,000
+25% +$144K
IMGN
31
DELISTED
Immunogen Inc
IMGN
$675K 0.49%
150,000
-40,000
-21% -$174K
ARVN icon
32
Arvinas
ARVN
$517M
$631K 0.46%
15,000
– –
CFRX
33
DELISTED
ContraFect Corporation
CFRX
$614K 0.45%
2,500
– –
TPTX
34
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$602K 0.44%
8,000
– –
CGEM icon
35
Cullinan Oncology
CGEM
$1.09B
$578K 0.42%
45,114
– –
APLS
36
DELISTED
Apellis Pharmaceuticals
APLS
$543K 0.4%
12,000
– –
CCXI
37
DELISTED
ChemoCentryx, Inc.
CCXI
$496K 0.36%
20,000
– –
NKTR icon
38
Nektar Therapeutics
NKTR
$2.21B
$486K 0.35%
8,533
– –
IRTC icon
39
iRhythm Holdings
IRTC
$3.69B
$432K 0.31%
4,000
– –
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$408K 0.3%
38,000
– –
BLUE
41
DELISTED
bluebird bio
BLUE
$406K 0.3%
4,900
+700
+17% +$54.3K
VTYX
42
DELISTED
Ventyx Biosciences
VTYX
$404K 0.29%
33,000
+8,000
+32% +$120K
KALV
43
DELISTED
KalVista Pharmaceuticals
KALV
$394K 0.29%
40,000
– –
SILK
44
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$364K 0.26%
10,000
– –
XNCR icon
45
Xencor
XNCR
$1.4B
$337K 0.25%
12,300
– –
XENE icon
46
Xenon Pharmaceuticals
XENE
$6.5B
$304K 0.22%
+10,000
New +$302K
PTGX icon
47
Protagonist Therapeutics
PTGX
$8.9B
$301K 0.22%
38,000
– –
KNSA icon
48
Kiniksa Pharmaceuticals
KNSA
$4.86B
$291K 0.21%
30,000
– –
ZNTL icon
49
Zentalis Pharmaceuticals
ZNTL
$373M
$225K 0.16%
8,000
– –
BCRX icon
50
BioCryst Pharmaceuticals
BCRX
$2.35B
$212K 0.15%
20,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Birchview Capital held 64 positions worth $137M, down 1% from $139M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Birchview Capital's Q2 2022 filing shows 1 new, 15 increased, 6 reduced and 4 closed positions. Its largest new stake was Xenon Pharmaceuticals: 10,000 shares worth $304K. The largest sale was Biogen, an estimated $2.06M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2022 buy was Xenon Pharmaceuticals: 10,000 shares worth $304K.
  • Birchview Capital added most to Ovintiv in Q2 2022, an estimated $2.58M increase.
  • Birchview Capital's biggest Q2 2022 reduction was Bristol-Myers Squibb, cutting an estimated $2M.
  • Birchview Capital fully exited Biogen in Q2 2022, selling an estimated $2.06M.
  • Birchview Capital's ten largest holdings make up 73% of its $137M portfolio in Q2 2022.
  • Birchview Capital opened 1 new position and closed 4 in Q2 2022.
  • Birchview Capital's portfolio value fell 1% quarter-over-quarter to $137M.

Based on Birchview Capital's 13F filing for Q2 2022, filed 12 Aug 2022.